EGFR and nasopharyngeal carcinoma: Targeted therapies on epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) have been tested in NPC patients in clinical practice according to the molecular biological characteristics of NPC [6].